ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors is a phase 3 interventional study registered as NCT05671510, led by OncoC4 with BioNTech SE, and active but no longer recruiting on the registry. Official title: Phase 3, Two-stage, Randomised Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors. Planned enrolment is 630 participants (estimated). The study started in 2023-06-28 and primary completion is expected in 2027-08-31. No results have been posted on ClinicalTrials.gov.